Evolution in management of testicular seminoma: Population-based outcomes with selective utilization of active therapies

C. Kollmannsberger, S. Tyldesley, C. Moore, K. N. Chi, N. Murray, S. Daneshmand, P. Black, G. Duncan, Brandon Hayes-Lattin, C. Nichols

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: In this article, we report the evolution of treatment with increased use of active surveillance for stage I disease as well as risk-adapted chemotherapy for disseminated disease and associated outcomes of testicular seminoma in a contemporary population-based cohort. Methods: All patients with histologically confirmed seminoma referred from 1999 to 2008 to the British Columbia Cancer Agency or Providence Cancer Center were retrospectively reviewed. Both institutions manage ~90% of testicular cancers in their respective area. Results: A total of 649 patients were included. Clinical stage (CS) distribution: CSI/II/III n = 545/87/17. For CSI, there was a progressive and marked decrease in the utilization of prophylactic radiation (RT), and corresponding increase in the use of active surveillance. No deaths related to seminoma were reported in CSI patients. CSII or CSIII patients received RT or International Germ Cell Cancer Collaborative Group (IGCCCG) risk-appropriate chemotherapy with 101 of 104 patients being in long-term remission and 3 patients dying from treatment complications. For the entire seminoma population,

Original languageEnglish (US)
Pages (from-to)808-814
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number4
DOIs
StatePublished - 2011

Fingerprint

Seminoma
Population
Therapeutics
Radiation
Hospital Distribution Systems
Drug Therapy
British Columbia
Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Neoplasms

Keywords

  • Active surveillance
  • Chemotherapy
  • Radiation
  • Seminoma

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Kollmannsberger, C., Tyldesley, S., Moore, C., Chi, K. N., Murray, N., Daneshmand, S., ... Nichols, C. (2011). Evolution in management of testicular seminoma: Population-based outcomes with selective utilization of active therapies. Annals of Oncology, 22(4), 808-814. https://doi.org/10.1093/annonc/mdq466

Evolution in management of testicular seminoma : Population-based outcomes with selective utilization of active therapies. / Kollmannsberger, C.; Tyldesley, S.; Moore, C.; Chi, K. N.; Murray, N.; Daneshmand, S.; Black, P.; Duncan, G.; Hayes-Lattin, Brandon; Nichols, C.

In: Annals of Oncology, Vol. 22, No. 4, 2011, p. 808-814.

Research output: Contribution to journalArticle

Kollmannsberger, C, Tyldesley, S, Moore, C, Chi, KN, Murray, N, Daneshmand, S, Black, P, Duncan, G, Hayes-Lattin, B & Nichols, C 2011, 'Evolution in management of testicular seminoma: Population-based outcomes with selective utilization of active therapies', Annals of Oncology, vol. 22, no. 4, pp. 808-814. https://doi.org/10.1093/annonc/mdq466
Kollmannsberger, C. ; Tyldesley, S. ; Moore, C. ; Chi, K. N. ; Murray, N. ; Daneshmand, S. ; Black, P. ; Duncan, G. ; Hayes-Lattin, Brandon ; Nichols, C. / Evolution in management of testicular seminoma : Population-based outcomes with selective utilization of active therapies. In: Annals of Oncology. 2011 ; Vol. 22, No. 4. pp. 808-814.
@article{34ec054747664122978db54f8a0ed041,
title = "Evolution in management of testicular seminoma: Population-based outcomes with selective utilization of active therapies",
abstract = "Background: In this article, we report the evolution of treatment with increased use of active surveillance for stage I disease as well as risk-adapted chemotherapy for disseminated disease and associated outcomes of testicular seminoma in a contemporary population-based cohort. Methods: All patients with histologically confirmed seminoma referred from 1999 to 2008 to the British Columbia Cancer Agency or Providence Cancer Center were retrospectively reviewed. Both institutions manage ~90{\%} of testicular cancers in their respective area. Results: A total of 649 patients were included. Clinical stage (CS) distribution: CSI/II/III n = 545/87/17. For CSI, there was a progressive and marked decrease in the utilization of prophylactic radiation (RT), and corresponding increase in the use of active surveillance. No deaths related to seminoma were reported in CSI patients. CSII or CSIII patients received RT or International Germ Cell Cancer Collaborative Group (IGCCCG) risk-appropriate chemotherapy with 101 of 104 patients being in long-term remission and 3 patients dying from treatment complications. For the entire seminoma population,",
keywords = "Active surveillance, Chemotherapy, Radiation, Seminoma",
author = "C. Kollmannsberger and S. Tyldesley and C. Moore and Chi, {K. N.} and N. Murray and S. Daneshmand and P. Black and G. Duncan and Brandon Hayes-Lattin and C. Nichols",
year = "2011",
doi = "10.1093/annonc/mdq466",
language = "English (US)",
volume = "22",
pages = "808--814",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Evolution in management of testicular seminoma

T2 - Population-based outcomes with selective utilization of active therapies

AU - Kollmannsberger, C.

AU - Tyldesley, S.

AU - Moore, C.

AU - Chi, K. N.

AU - Murray, N.

AU - Daneshmand, S.

AU - Black, P.

AU - Duncan, G.

AU - Hayes-Lattin, Brandon

AU - Nichols, C.

PY - 2011

Y1 - 2011

N2 - Background: In this article, we report the evolution of treatment with increased use of active surveillance for stage I disease as well as risk-adapted chemotherapy for disseminated disease and associated outcomes of testicular seminoma in a contemporary population-based cohort. Methods: All patients with histologically confirmed seminoma referred from 1999 to 2008 to the British Columbia Cancer Agency or Providence Cancer Center were retrospectively reviewed. Both institutions manage ~90% of testicular cancers in their respective area. Results: A total of 649 patients were included. Clinical stage (CS) distribution: CSI/II/III n = 545/87/17. For CSI, there was a progressive and marked decrease in the utilization of prophylactic radiation (RT), and corresponding increase in the use of active surveillance. No deaths related to seminoma were reported in CSI patients. CSII or CSIII patients received RT or International Germ Cell Cancer Collaborative Group (IGCCCG) risk-appropriate chemotherapy with 101 of 104 patients being in long-term remission and 3 patients dying from treatment complications. For the entire seminoma population,

AB - Background: In this article, we report the evolution of treatment with increased use of active surveillance for stage I disease as well as risk-adapted chemotherapy for disseminated disease and associated outcomes of testicular seminoma in a contemporary population-based cohort. Methods: All patients with histologically confirmed seminoma referred from 1999 to 2008 to the British Columbia Cancer Agency or Providence Cancer Center were retrospectively reviewed. Both institutions manage ~90% of testicular cancers in their respective area. Results: A total of 649 patients were included. Clinical stage (CS) distribution: CSI/II/III n = 545/87/17. For CSI, there was a progressive and marked decrease in the utilization of prophylactic radiation (RT), and corresponding increase in the use of active surveillance. No deaths related to seminoma were reported in CSI patients. CSII or CSIII patients received RT or International Germ Cell Cancer Collaborative Group (IGCCCG) risk-appropriate chemotherapy with 101 of 104 patients being in long-term remission and 3 patients dying from treatment complications. For the entire seminoma population,

KW - Active surveillance

KW - Chemotherapy

KW - Radiation

KW - Seminoma

UR - http://www.scopus.com/inward/record.url?scp=79953324912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953324912&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq466

DO - 10.1093/annonc/mdq466

M3 - Article

C2 - 20926549

AN - SCOPUS:79953324912

VL - 22

SP - 808

EP - 814

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -